Guggenheim analyst Dana Flanders came out to defend Bausch Health Companies (NYSE: BHC), saying the sell-off is overdone.

• incremental updates unlikely to inspire near-term confidence, but sell-off overdone.

The analyst reiterated a Buy rating and $36.00 price target on BHC.

For an analyst ratings summary and ratings history on Bausch Health Companies click here. For more ratings news on Bausch Health Companies click here.

Shares of Bausch Health Companies closed at $28.05 yesterday.